SOST and osteogenesis imperfecta: Aptscl56 had no influence in the loop3-independent cardiovascular protective effect of sclerostin for OI mice. Humanized therapeutic sclerostin antibody shows high risk of cardiac ischemic events in clinical trials (BRIDGE and ARCH).